Lilly And China's Hisun Complete Technology Transfer For Antibiotic Capreomycin For TB
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - Eli Lilly and Chinese active pharmaceutical ingredient provider Hisun recently announced the completion of a technology transfer under which Lilly transferred technology to Hisun to produce finished products and API of its tuberculosis drug capreomycin
You may also be interested in...
Hisun’s pre-qualification approval for capreomycin to treat second-line active tuberculosis cases may help bring costs down for a drug increasingly in demand as multi-drug resistant patients multiply worldwide.